secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001171843-25-000457
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeyondSpring sells SEED Therapeutics stake for $35.4M to fund Plinabulin trials
-------------------------------------------------------------------------------

- Sells 8,333,637 Series A-1 Preferred Shares at $4.25/share to three investors for ~$35.4M gross proceeds.
- After all closings, BeyondSpring and subsidiary will own ~14.4% of SEED (down from ~41% initially).
- Proceeds advance Plinabulin to registrational studies; DUBLIN-3 showed OS benefit in NSCLC.
- 303 study of Plinabulin + pembrolizumab/docetaxel achieved 89.3% DCR and 8.6 mo median PFS.
- 302 study enrolling first-line ES-SCLC patients; Plinabulin has GEF-H1 immune activation mechanism.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325000457/0001171843-25-000457-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325000457/f8k_012725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-000457

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer